Trial · NCT02304302
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2) | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the Paired Associates Learning (PAL) From the Cambridge Neuropsychological Test Automated Battery (CANTAB) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2) | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the Recall of Digits Forward (From the Differential Ability Scales; DAS-II) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the Pattern Recognition Memory (PRM; Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Working Memory (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Span (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| SECONDARY | Efficacy of the Drug Memantine as Assessed by Change in Score on the The Go - No Go Task | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). Notice that, for this specific test, some participants stopped midway. | ms | MEAN |
| SECONDARY | Safety and Tolerability of the Drug Memantine as Assessed by Change in QTc Interval | baseline and 16 weeks from start of treatment | The analysis population consisted of all participants who started treatment and had good-quality ECGs before and after the start of memantine treatment, whether or not they completed the entire treatment. | ms | MEAN |
| OTHER_PRE_SPECIFIED | Intellectual Functioning of the Participants as Assessed by Change in Score on the Matrices Subtest of the Differential Ability Scales-II (DAS-II) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Linguistic Functioning of the Participants as Assessed by Change in Score on the Test for Reception of Grammar 2nd Edition (TROG-II) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Linguistic Functioning of the Participants as Assessed by Change in Score on the Peabody Picture Vocabulary Test-IV (PPVT-IV) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). | score on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Adaptive/Behavioral Functioning of the Participants as Assessed by Change in Score on the Scales of Independent Behavior-Revised (SIB-R) | baseline and 16 weeks from start of treatment | The analysis population consisted of participants who completed 16 weeks of treatment and had neuropsychological assessments at baseline (T1) and after treatment (T2). Note that some participants chose not to undergo the questionnaire. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02304302/outcomes